Nurix Therapeutics
Tracked across 2 events · 88 articles · First seen May 20, 2026 · Last active Jun 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Roche has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg (also known as NX-5948), an investigational Bruton's Tyrosine Kinase (BTK) degrader. Roche will pay Nurix Therapeutics an…
Impact: Nurix Therapeutics has secured a significant collaboration with Roche for its BTK degrader bexobrutideg, receiving a substantial upfront payment and access to Roche's global development and commercialization infrastructure. This partnership validates Nurix's targeted protein degradation platform and provides resources for advancing bexobrutideg across multiple therapeutic areas.
Jun 07, 2026 · 22 articles
Business
Global stock markets experienced a significant rally, primarily fueled by a stronger-than-expected quarterly report from Nvidia, which saw its profit and revenue surge due to high demand for its AI chips. This boosted technology shares…
Impact: Nurix Therapeutics' stock was up more than 17% after Roche agreed to pay up to $2.3 billion for rights to an experimental blood-cancer drug.
May 20, 2026 · 66 articles
90
Nurix Therapeutics received upfront payment RocheRoche, Nurix Therapeutics...
80
Nurix Therapeutics will co-commercialize RocheRoche, Nurix Therapeutics...
80
Roche will co-commercialize Nurix TherapeuticsRoche, Nurix Therapeutics...
75
Nurix Therapeutics will cover costs RocheRoche, Nurix Therapeutics...
75
Roche entered into agreement Nurix TherapeuticsRoche, Nurix Therapeutics...
75
Roche will cover costs Nurix TherapeuticsRoche, Nurix Therapeutics...
57
Roche entered into agreement Nurix TherapeuticsNvidia Earnings, Samsung...
NEWSDESK
Track Nurix Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard